Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. 2018

Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

OBJECTIVE To evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in China. METHODS In the retrospective study, Data were collected and included prolactin, testosterone and estradiol levels of 30 female patients with risperidone monotherapy. In the prospective study, Another 30 female schizophrenic patients were randomized to receive risperidone or adjunctive aripiprazole for six weeks. Serum prolactin, testosterone and estradiol levels were measured. RESULTS Serum prolactin, testosterone and estradiol levels in both studies were significantly decreased after risperidone treatment compared with baseline (P<0.05), and prolactin levels remained at a high level. Serum prolactin levels in the adjunctive aripiprazole group were significantly decreased after treatment compared with baseline in the prospective study (P<0.05). Doses of 5 mg and 10 mg of adjunctive aripiprazole achieved the same efficacy at the end of treatment. CONCLUSIONS Risperidone treatment decreased serum testosterone and estradiol levels. Adjunctive aripiprazole relieved hyperprolactinemia, but had no effect on testosterone or estradiol levels. Adjunctive aripiprazole at a dose of 5 mg is recommended for clinical use.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068180 Aripiprazole A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression. 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone,Abilify,Aripiprazol,OPC 14597,OPC-14597
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone

Related Publications

Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
May 2002, The Journal of clinical psychiatry,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
September 2021, Neuropsychopharmacology reports,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
July 2007, International clinical psychopharmacology,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
September 2000, Clinical therapeutics,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
March 2007, Progress in neuro-psychopharmacology & biological psychiatry,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
June 2016, Psychiatry research,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
October 2010, Journal of clinical psychopharmacology,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
January 2018, Neuropsychiatric disease and treatment,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
January 2018, Endocrine, metabolic & immune disorders drug targets,
Xiao-Jia Jiang, and Fu-Xi Wu, and Jian-Ping Zhang, and Lei Shi, and Jin-Qing Hu, and Hai-Zhen Zhu, and Bing Xiao, and Wei-Cheng Lin, and Yu-Guan Wen, and De-Wei Shang
February 2013, Journal of clinical psychopharmacology,
Copied contents to your clipboard!